MGX

Metagenomi Therapeutics, Inc.
CAPPED RATING

Metagenomi Therapeutics, Inc. (MGX) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Momentum (D).

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
B
Factor Score 3.4 / 5.0
Growth
C-
Factor Score 2.1 / 5.0
Profitability
C-
Factor Score 2.1 / 5.0
Momentum
D
Factor Score 1.4 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.4
EV / EBITDA 0.4
Rev Growth YoY -74.8%
Gross Margin 0.0%
Price Return 3M -42.0%
Price Return 12M -67.5%
Catalyst Signal 0.00
Market Cap $27.0M
TTM Revenue $7.1M
Price / Sales 3.8
ROE -69.4%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B (3.4) C- (2.1) C- (2.1) D (1.4) C+ (2.6) C (2.3)
2026-11-06 B (3.4) B- (3.0) C (2.4) D+ (1.5) C+ (2.7) C+ (2.6)
2026-10-30 B (3.3) B- (2.9) C+ (2.5) D+ (1.7) C+ (2.7) C+ (2.6)
2026-10-23 B (3.3) B- (2.9) C+ (2.5) D+ (1.6) C+ (2.6) C+ (2.6)
2026-10-16 B (3.4) B- (3.0) C+ (2.5) D+ (1.7) C+ (2.6) C+ (2.6)
Page 1 of 4